Spyre Therapeutics (SYRE) Treasury Shares (2015 - 2025)
Spyre Therapeutics' (SYRE) quarterly Treasury Shares came in at $76932.0 in Q4 2025, down 33.33% YoY from $115398.0 in Q4 2024, and down 33.33% on a QoQ basis from $115398.0 in Q4 2024.
Spyre Therapeutics (SYRE) Treasury Shares (2015 - 2025) Analysis & Trends
Spyre Therapeutics (SYRE) has 8 years of Treasury Shares data on file, last reported at $76932.0 in Q4 2025.
- Quarterly Treasury Shares fell 33.33% year-over-year to $76932.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $76932.0 (down 33.33% YoY) and the FY2025 annual result came in at $76932.0, down 33.33% from the prior year.
- Treasury Shares fell to $76932.0 in Q4 2025, from $115398.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $1.1 million in Q3 2023 to a low of $76932.0 in Q4 2025.
- A 4-year average of $326981.1 and a median of $181500.0 in 2022 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2023 — Treasury Shares jumped 624.0% — and 2025, when it sank 33.33%.
- Tracing SYRE's Treasury Shares over 4 years: stood at $150000.0 in 2022, then changed by 0.0% to $150000.0 in 2023, then fell by 23.07% to $115398.0 in 2024, then plunged by 33.33% to $76932.0 in 2025.
- The last three Treasury Shares figures came in at $76932.0 (Q4 2025), $115398.0 (Q4 2024), and $272000.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 76,932.00 |
| Dec 31, 2025 | 76,932.00 |
| Dec 31, 2024 | 115,398.00 |
| Dec 31, 2024 | 115,398.00 |
| Mar 31, 2024 | 272,000.00 |
| Mar 31, 2024 | 272,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Dec 31, 2023 | 150,000.00 |
| Sep 30, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 721,000.00 |
| Jun 30, 2023 | 721,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 181,500.00 |
| Jun 30, 2022 | 181,500.00 |
| Mar 31, 2022 | 190,000.00 |
| Mar 31, 2022 | 190,000.00 |
| Dec 31, 2018 | 6,863.00 |
| Dec 31, 2018 | 6,863.00 |